Preemptive analgesia with parecoxib in procedure for prolapse and hemorrhoids

Abstract

Objective To explore the efficacy and safety of preemptive analgesia with parecoxib in procedure for prolapse and hemorrhoids (PPH). Methods 70 ASA Ⅰ - Ⅱ patients scheduled for PPH were randomly assigned to receive intravenous parecoxib of 40 mg 5 min before anesthesia as preemptive analgesia (parecoxib group), or 0.9％ NS of 5 ml (control group). The adverse reactions and use of analgetics were recorded postoperatively at hours 4, 8, 12, and 24. The analgetic effect was measured with VAS and the satisfactory degree in the patients was evaluated with BCS. Results The number of patients using supplementary analgetics after the procedure was smaller in the parecoxib group than in the control group (2 vs. 7,P＜0.05＝. The VAS scale was lower in the parecoxib group than in the control group at the four time points (1.0 ± 0.6vs 1.4 ± 0.7, 2.6 ± 0.6vs3.1 ± 0.8, 3.6 ± 0.5 vs4.1 ± 0.7, and 1.8 ± 0.6 vs2.2 ± 0.8; P＜ 0.05＝, whereas the BCS scale was higher (3.5 ± 0.5 vs 3.1 ± 0.6, 2.4 ± 0.4 vs 2.0 ± 0.5, 1.7 ± 0.5 vs 1.2 ± 0.6, and 2.9 ± 0.5 vs 2.6 ± 0.5, P＜ 0.05). There was no significant difference in adverse reactions between the two groups (P＞ 0.05). Conclusions Preemptive analgesia with parecoxib in procedure for prolapse and hemorrhoids can obviously relieve postsurgical pain with higher satisfaction and fewer adverse reactions. It is safe and reliable. Key words: Parecoxib; Procedure for prolapse and hemorrhoids; Preemptive analgesia